NEW YORK — 4basebio on Thursday posted a 5 percent year-over-year decline in revenues for the third quarter, reflecting a reduction in US sales following the closure of the company's San Diego site. In addition, it has approved the spinoff of its DNA manufacturing business.
For the three-month period ended September 30, 4basebio's revenues fell to €289,000 ($340,800) from €305,000 a year earlier, as a bulk sale of enzymes from the company's Spanish operations partially offset the lower US sales.